Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Introduction: definition and classification of the human herpesviruses
- Part II Basic virology and viral gene effects on host cell functions: alphaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: betaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: gammaherpesviruses
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HSV-1 and HSV-2
- Part III Pathogenesis, clinical disease, host response, and epidemiology: VZU
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HCMV
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HHV- 6A, 6B, and 7
- Part III Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses
- Part IV Non-human primate herpesviruses
- Part V Subversion of adaptive immunity
- Part VI Antiviral therapy
- Part VII Vaccines and immunothgerapy
- Part VIII Herpes as therapeutic agents
- 76 Herpesviruses as therapeutic agents
- Index
- Plate section
- References
76 - Herpesviruses as therapeutic agents
from Part VIII - Herpes as therapeutic agents
Published online by Cambridge University Press: 24 December 2009
Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Introduction: definition and classification of the human herpesviruses
- Part II Basic virology and viral gene effects on host cell functions: alphaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: betaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: gammaherpesviruses
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HSV-1 and HSV-2
- Part III Pathogenesis, clinical disease, host response, and epidemiology: VZU
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HCMV
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HHV- 6A, 6B, and 7
- Part III Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses
- Part IV Non-human primate herpesviruses
- Part V Subversion of adaptive immunity
- Part VI Antiviral therapy
- Part VII Vaccines and immunothgerapy
- Part VIII Herpes as therapeutic agents
- 76 Herpesviruses as therapeutic agents
- Index
- Plate section
- References
Summary
Introduction
After more than a decade of intensive research and development efforts, the translation of promising viral-based gene therapies from the research lab to the clinic is both promising and unexpectedly challenging. Many of the same properties that make viral vectors attractive candidates to deliver genes for therapeutic purposes also impede the path to successful clinical development.
Vectors for clinical use must be manufactured in relatively high yields such that hundreds of thousands or even millions of “doses” can be generated in a safe and cost-effective manner. Moreover, the resulting vector must exhibit genetic as well as structural stability, withstand storage at various temperatures for up to several years, and cause little or no toxicity in animals, and ultimately in humans.
Herpes simplex viruses (HSV), while widespread in nature, have not been tested in human clinical studies as often as several other commonly used vectors, such as adenovirus, adeno-associated viruses (AAV), and retroviruses. In many ways however, HSV is emerging as a viable therapeutic platform and several clinical studies are either ongoing or planned for the very near future. The reason for this increased focus on HSV is due in part attributable to the unique properties that make HSV a stable and potentially potent vector for controlled gene delivery. In addition, the increasing experience with replication-competent vectors in human clinical studies has made it more familiar with clinicians.
Properties of therapeutic HSV vectors
Therapeutic HSV can be characterized as replication-competent or replication-defective.
- Type
- Chapter
- Information
- Human HerpesvirusesBiology, Therapy, and Immunoprophylaxis, pp. 1341 - 1352Publisher: Cambridge University PressPrint publication year: 2007
References
, , et al. (1998). Enhancement of replication of genetically engineered herpes simplex virus by ionizing radiation: a new paradign for destruction of therapeutically intractable tumors. Gene Ther., 5, 160–165.CrossRefGoogle Scholar
, , , , , and (1999). Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum. Gene Ther., 13, 627–639.CrossRefGoogle Scholar
, , et al. (1999). Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin. Cancer Res., 5, 1517–1522.Google ScholarPubMed
, , , and (1999). Replication-competent herpes simpelx virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia, 1, 162–169.CrossRefGoogle ScholarPubMed
, , et al. (2002). In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann. Neurol., 51, 19–27.CrossRefGoogle ScholarPubMed
, , et al. (2003). Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur. J. Neurosci., 17, 732–740.CrossRefGoogle ScholarPubMed
and (1992). The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Natl Acad. Sci. USA, 89, 3266–3270.CrossRefGoogle ScholarPubMed
, , , and (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science, 250, 1262–1266.CrossRefGoogle ScholarPubMed
, , and (1989) Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob. Agents Chemother., 33, 1395–1399 (Erratum appears in Antimicrob. Agents Chemother., 33, 1827).CrossRefGoogle ScholarPubMed
, , and (1985). Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J. Virol., 56, 558–570.Google ScholarPubMed
, , and (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell. Biol., 3, 745–750.CrossRefGoogle ScholarPubMed
Fong, Y., Kermeny, N., Jarnagin, W. et al. (2002). Phase I study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. ASCO Annual Meeting. Orlando, FL, May 18–21.
, , et al. (1996). Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol., 70, 7190–7197.Google ScholarPubMed
, , et al. (1999). Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J. Virol., 73, 519–532.Google ScholarPubMed
and (1988). Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology, 166, 41–51.CrossRefGoogle ScholarPubMed
, , , , , and (2001). Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther., 8, 551–556.CrossRefGoogle ScholarPubMed
, , et al. (2002a). Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann. Neurol., 52, 662–665.CrossRefGoogle Scholar
, , , , , and (2002b). Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes, 51, 2227–2232.CrossRefGoogle Scholar
, , , , and (2003). Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain, 102, 135–142.CrossRefGoogle ScholarPubMed
, , and (2002). HSV1716 persistence in primary human glioma cells in vitro. Gene Ther., 9, 1194–1198.CrossRefGoogle ScholarPubMed
, , et al. (2004). HSV 1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther., 11, 1648–1658.CrossRefGoogle Scholar
, , and (1997). The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl Acad. Sci. USA, 94, 843–848.CrossRefGoogle ScholarPubMed
, , and (2004). Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector. Hum. Gene Ther., 15, 495–508.CrossRefGoogle ScholarPubMed
, , et al. (1999). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol., 73, 6319–6326.Google ScholarPubMed
, , et al. (2003). Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum. Gene Ther., 14, 277–297.CrossRefGoogle ScholarPubMed
, , , et al. (1998). Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther., 5, 1593–1603.CrossRefGoogle ScholarPubMed
, , et al. (2001). Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J. Virol., 75, 4343–4356.CrossRefGoogle ScholarPubMed
, , and (1989). Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient. J. Virol., 63, 18–27.Google ScholarPubMed
, , and (2001). Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet, 357, 525–526.CrossRefGoogle ScholarPubMed
, , et al. (1996). Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc. Natl Acad. Sci. USA, 93, 11319–11320.CrossRefGoogle ScholarPubMed
, , , , and (1992). Expanded spectrum of viral therapy in the treatment of nervous system tumors. J. Neurosurg. 77, 590–594.CrossRefGoogle ScholarPubMed
, , , and (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery, 32, 597–603.CrossRefGoogle Scholar
, , , , and (2000a). Genetically engineered HSV in the treatment of glioma: a review. Rev. Med. Virol., 10, 17–30.3.0.CO;2-G>CrossRefGoogle Scholar
, , et al. (2000b). Conditionally replicating herpes simplex, virus., mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 7, 867–874.CrossRefGoogle Scholar
, , , , and (2000). Long-term transgene expression in mice infected with a herpes simplex virus type 1 mutant severely impaired for immediate-early gene expression. J. Virol., 74, 956–964.CrossRefGoogle ScholarPubMed
, , , , and (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252, 854–856.CrossRefGoogle ScholarPubMed
(1991). Genetically engineered attenuated herpes simplex viruses. Rev. Infect. Dis., 13 Suppl 11, S895–S897.CrossRefGoogle ScholarPubMed
, , and (1988). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis., 158, 602–614.CrossRefGoogle ScholarPubMed
, , , and (1990). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis., 162, 313–321.CrossRefGoogle Scholar
and (2000). Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res., 60, 5714–5722.Google Scholar
, , , , and (2001). Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1. Mol. Ther., 3, 160–168.CrossRefGoogle ScholarPubMed
, , and (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res., 54, 3963–3966.Google ScholarPubMed
, , , , and (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1, 938–943.CrossRefGoogle ScholarPubMed
, , et al. (1998). Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Resi., 58, 5731–5737.Google ScholarPubMed
, , , et al. (2000). Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J. Virol., 74, 5604–5618.CrossRefGoogle ScholarPubMed
, , et al. (2002). The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther., 9, 398–406.CrossRefGoogle ScholarPubMed
, , et al. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. [see comment]. Gene Ther., 7, 859–866.CrossRefGoogle Scholar
, , , , and (1997). Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Invest. Dermatol., 108, 933–937.CrossRefGoogle ScholarPubMed
, , and (1995). Functional interactions between herpes simplex virus immediate-early proteins during infection: gene expression as a consequence of ICP27 and different domains of ICP4. J. Virol., 69, 5705–5715.Google ScholarPubMed
, , and (1997). The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol., 71, 4614–4625.Google ScholarPubMed
, , and (1998). Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol., 72, 3307–3320.Google ScholarPubMed
, , , , , and (2002). Connexin 43-mediated bystander effect in two rat glioma cell models. Cancer Gene Ther., 9, 149–155.CrossRefGoogle ScholarPubMed
, , and (2002). Tetracycline-regulated gene expression in replication-incompetent herpes simplex virus vectors. Hum. Gene Ther., 13, 2113–2124.CrossRefGoogle ScholarPubMed
, , , and Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol., 65, 203–226.CrossRef
and (1982). The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell, 30, 295–304.CrossRefGoogle ScholarPubMed
, , , and (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther., 10, 385–393.CrossRefGoogle Scholar
, , et al. (1994). The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J. Gen. Virol., 75, 2059–2063.CrossRefGoogle ScholarPubMed
, , , , and (2001). An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat. Biotechnol., 19, 1067–1070.CrossRefGoogle ScholarPubMed
, , et al. (2002). Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. J. Virol., 76, 7150–7162.CrossRefGoogle ScholarPubMed
, , , and (1996). Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J. Virol., 70, 6358–6369.Google ScholarPubMed
, , , , , and (1999). Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc. Natl Acad. Sci. USA, 96, 4078–4083.CrossRefGoogle ScholarPubMed